Printer Friendly

GILEAD COMPLETES PHASE II OF HIV INTEGRASE INHIBITOR GS 9137.

Gilead Sciences, Inc. (Nasdaq:GILD), Foster City, Calif. has completed the Phase II clinical trial of GS 9137, a novel oral HIV integrase inhibitor. The clinical study met its primary endpoint of non-inferiority in viral load reduction in HIV-positive patients receiving 50 mg or 125 mg of GS 9137 once daily, each boosted with 100 mg of ritonavir, in combination with an optimized background antiretroviral regimen compared to a boosted comparator protease inhibitor regimen (p=0.02 for the 125 mg arm).

This ongoing Phase II study is a partially-blinded, randomized, active-controlled, 48-week clinical trial to evaluate the non-inferiority of once-daily GS 9137 versus boosted comparator protease inhibitors (CPI/r) in highly treatment-experienced HIV-infected patients. After week eight, the GS 9137 20 mg arm was closed due to a high rate of virologic failure. At this time, the addition of darunavir or tipranavir to the GS 9137 study arms was permitted, following the availability of data demonstrating a lack of drug interactions between both protease inhibitors and GS 9137. The primary endpoint of the study was DAVG24, a measure of viral load reduction over 24 weeks. Integrase inhibitors are an investigational class of antiretrovirals that interfere with HIV replication by blocking the ability of the virus to integrate into the genetic material of human cells. Novel classes of HIV-fighting drugs are needed as patients live longer and exhaust currently available treatment options.

About GS 9137

GS 9137, also known as JTK-303, was licensed by Gilead from Japan Tobacco Inc. (JT) in March 2005. Under the terms of the company's agreement with JT, Gilead has exclusive rights to develop and commercialize GS 9137 in all countries of the world, excluding Japan where JT retains rights. As an investigational compound, GS 9137 has not yet been determined safe or efficacious in humans for its ultimate intended use.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

For more information, visit http://www.gilead.com or call 1-800-GILEAD-5 or 650/574-3000.
COPYRIGHT 2007 Worldwide Videotex
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Biotech Business
Article Type:Clinical report
Date:Apr 1, 2007
Words:370
Previous Article:SIGNIFICANT PHASE III CIMZIA RESULTS IN RHEUMATOID ARTHRITIS.
Next Article:NOVOZYMES OPENS IOWA CENTER FOR ETHANOL/BIOFEUL RESEARCH.
Topics:


Related Articles
TRIMERIS/HOFFMAN LA ROCHE PROGRESS WITH HIV FUSION INHIBITORS.
New Compounds Inhibit HIV in Lab.
FDA APPROVES GILEAD'S ANTI-HIV DRUG VIREAD.
Retroviruses conference: Some new drugs in the pipeline.
Chart on drugs in development. (HIV Pipeline).
Integrase inhibitors: first clear success in human trial.
The next line of attack: the previous generation of anti-HIV drugs changed AIDS from an untreatable epidemic into a survivable disease. The next crop...
The 14th Conference on Retroviruses and Opportunistic Infections (CROI): Los Angeles, February 25th-28th.
Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters